In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct purchaser complaint in this case. The case alleges that the successive brand manufacturers of Niaspan (Kos, Abbott, Abbvie) paid successive would-be generic competitors (Duramed, Barr, and Teva) to delay launching less-expensive generic versions of Niaspan, in what is commonly known as a “pay-for-delay” conspiracy.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 04/05/2013
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771